Group 1 - The article defines technology transfer and technology development as business activities related to the transfer of technology, research and development services, and technical consulting [1][8] - Technology transfer fees and technology development fees can only issue a general VAT invoice with a tax rate of "exempt" and cannot issue a special VAT invoice [2][3] - Technical consulting and services related to technology transfer and development must be invoiced together with the price of the technology transfer or development [3][8] Group 2 - Exemptions from VAT for technology transfer include both patented and non-patented technologies, as well as related technical consulting and services [8][9] - There is no need for prior filing to enjoy VAT exemption for technology development income [10] - Eligible technology transfer income can also enjoy corporate income tax benefits, with a portion of technology transfer income not exceeding 5 million yuan exempt from corporate income tax [11]

Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) has entered into a technology development contract with its wholly-owned subsidiary Jiangsu Corning Jereh Biopharmaceutical Co., Ltd. and Suzhou Corning Jereh Biotechnology Co., Ltd. to enhance its development of bispecific antibody-drug conjugates (ADCs) [1] Group 1 - The contract, signed on August 8, 2025, involves Suzhou Corning Jereh providing technical development services, including the development of production processes and analytical methods for ADC candidates [1] - Suzhou Corning Jereh has been a reliable service provider since 2018, possessing extensive experience and competitiveness in process optimization services [1] - The company believes that the contract will help optimize existing production and R&D processes, reduce related costs, and positively impact future product development, manufacturing, and IND applications [1]

Group 1 - The company plans to globally offer 67.91 million shares, with 6.79 million shares for Hong Kong and 61.12 million shares for international sale [1] - The subscription period is from May 19 to May 22, with a maximum offer price of HKD 10.68 per share and an entry fee of approximately HKD 5,393.85 for 500 shares [1] - The total expected fundraising amount is HKD 617 million, with a net amount of HKD 505 million, which will be used for technology development, enhancing data analysis capabilities, and expanding revenue sources [1] Group 2 - The company has introduced cornerstone investors including Shen Zhenyu, Yulong International Capital Limited, and Timber Kangaroo Capital Limited, who will subscribe to approximately 14.55 million shares at the offer price [1] - The company is expected to be listed on the main board on May 27, 2025, with China International Capital Hong Kong Securities Limited and CMB International Capital Limited as joint sponsors [1] Group 3 - The company's main business includes professional design services, software development, IT consulting, and sales of various medical devices and consumer products [2] - The company reported net profits of CNY 345 million, CNY 182 million, and CNY 59.16 million for the fiscal years 2023, 2024, and the first quarter of 2025, with year-on-year changes of 87.57%, -47.28%, and 38.21% respectively [3]

以下文章来源于远川汽车评论 ，作者熊宇翔 彭苏平 去年6月，比亚迪董事长王传福在股东大会上陈述了自己的高端观： "我们不可能过度营销，也不可能通过巨大流量来谋求一时的发展，真正创造高端品牌还得靠产品力，产品 力的核心还是在于技术和创新。[1]" 近一年时间，比亚迪新技术易四方、易三方、云辇等齐出，创下一个个新的工业奇迹，将高端品牌仰望、 腾势、方程豹的新车型产品力武装到牙齿。 远川汽车评论 . 不止是汽车 不过，肉眼观测上技术含量爆表的比亚迪，过去一年时间在高端市场的表现，全然不如在20万以下市场那 般风卷残云： 仰望高开低走，百万级越野豪车U8上市四个月突破5000辆后销量迅速放缓，如今终端优惠已悄悄突破10万 元； 图源：懂车帝 腾势在MPV车型D9爆火之后一直苦苦寻觅第二增长点，看似量大管饱的N7、N8都未能担此大任，N7不得 不在改款时怒降8万改走性价比路线，而用上全新技术平台、斥巨资打造的Z9/Z9GT也没能一炮而红，眼下 寄望于刚刚上市的旗舰SUV N9。 方程豹首款车型豹5摸到了30万元的门板，去年不堪压力降了5万才保住销量，而最新发布的钛3更是向现实 低头，售价不到14万，重新回到了比亚迪的舒 ...